AltaThera Pharmaceuticals, a hospital specialty pharmaceutical company focused on commercializing innovative drugs aimed at improving outcomes and reducing hospital costs, chose Dexur’s App Suite to help scale the operations of the company. AltaThera recently received approval from the FDA for new indications of Sotalol IV, to help hospitals manage patients with Afib.
“We chose Dexur because it integrates the myriad of applications such as CRM, Sales Reporting, Medical Information Request (MIRF) and Sunshine Reporting into a single platform that our sales, commercial and other operations can utilize to scale” said Jodi Devlin, AltaThera's CEO
Altathera’s use of Dexur Apps include:
Dexur not only brings the core applications but also the implementation services to customize it to fit the precise needs of Altathera. Unlike, other technology platforms where the implementation services are disconnected underlying technology. This helps Altathera manage costs while scaling the operations of the operations effectively.
About Dexur: Dexur provides technology and data solutions to Life Sciences, Hospitals, and healthcare organizations. Dexur's Life Sciences App suite provides a comprehensive set of applications to help Biopharma, Medical Device, and Life Sciences companies scale effectively.
“Dexur’s App Suite and implementation services is a key strategic partner to help scale ClearFlow. The breadth and depth of Dexur’s offering across data, sales analytics, and marketing automation has made Dexur a critical element in articulating ClearFlow’s value to healthcare providers” said Paul Molloy, CEO of ClearFlow.
ClearFlow’s first commercial solution, the PleuraFlow® ACT® System, improves outcomes for cardiac surgery patients by preventing the most harmful postoperative complications associated with retained blood syndrome (RBS). The System seamlessly integrates into clinical workflow.
“Dexur’s hospital-specific disease burden data combined with personalized microsites elevates our marketing automation to a new level. The program represents a breakthrough in enabling personalized communication at scale, unique in the medical device community” said Stephen Bumb, Vice President Global Marketing at ClearFlow.
ClearFlow’s use of Dexur App suite includes:
“Dexur empowers our representatives by delivering the most relevant data with key machine-generated talking points. This enables our reps to have meaningful conversations about RBS and its impact on cardiac surgery outcomes. We are better equipped to help our customers. Best of all, the solution is easy to navigate and is at the team’s fingertips when they are engaged with customers.” said Michael Elniski, Vice President Global Sales at ClearFlow.
Heron Therapeutics, Inc., a commercial-stage biotechnology company utilizes Dexur’s App suite to increase velocity in commercial operations.
Heron’s use of Dexur’s App suite to increase speed and efficiency in operations include:
“The breadth of Dexur’s App Suite plus the quick customization, implementation and support services have been critical in increasing the velocity of Heron’s commercial operations and supporting our front line reps and commercial operations teams.” said Kourosh Mobini, Sr. Director, Commercial Operations at Heron Therapeutics.
Dexur provides critical volume and quality outcomes data to Orthopedic Network News, a leading Orthopedic research publication, that is read by orthopedic surgeons and hospitals. The data has been used to publish statistics on quality outcomes, shifts in care from inpatient to outpatient and other emerging trends.
“I have been a customer of Dexur’s since 2018. Each quarter we publish statistics on the number of orthopedic procedures paid by Medicare in Orthopedic Network News, and Curvo Labs Spotlight. I have used a variety of sources for national statistics in the past, but have found Dexur to be most in depth, economical, accommodating and responsive. They have been flexible in providing access for colleagues and developing custom reports. In short, they have been a valued resource for national, hospital and surgeon specific healthcare data. I have found that Dexur has been extremely accurate, timely, and responsive to various tweaks on questions that come up, which have included issues such as the number of endovascular heart valves, number of outpatient knee replacements, in- and outpatient spine surgeries, and top hospitals and top states performing procedures. And Dexur’s commitment to maintaining the data over multiple time periods has been key to identifying underlying trends.” said, Stan Mendenhall, Editor of Orthopedic Network News
Dexur & researchers from top institutions such as Harvard Medical School collaborate to publish several Real-World Evidence (RWE) based research papers in peer-reviewed publications.
“Dexur and our research team at the Brigham & Women's Hospital and Harvard Medical School have collaborated on multiple research projects related to exploring the impact of opioid use on healthcare systems and patient outcomes, as well as other research topics. Dexur has aggregated one of the largest anonymized medical claims databases in the US and their ability to harness that data to produce in-depth hospital-level quality outcomes disease is unique. Dexur's research team has been very flexible in understanding the scope of the research and has been very quick in their turnaround time to answer key questions and analyze data.” said Dr. Richard Urman, Associate Professor, Harvard Medical School Anesthesia and Pain Management
McLaren Bay Region has announced Dr. Ramesh Cherukuri has been ranked No. 1 in all of Michigan with Most Experience in Coronary Bypass Surgeries by Dexur, a data-driven hospital and healthcare news and research organization. "We are honored Dr. Cherukuri has been recognized with this prestigious ranking" says Clarence Sevillian, Regional CEO, at McLaren. "When our patients choose McLaren for their cardiac care, we want them to be assured that our experienced medical teams are doing what's best when they need it the most.
McLaren Health Care has also launched billboards to showcase Dexur's ranking of Dr. Cherukuri.
Intrepid USA, a leading home health and hospice provider, chose Gridlex’s Dexur data and marketing collateral solution to enhance quality outcomes for referral partners and patients.
Mike Gregory, The Chief Patient Advocacy Officer at Intrepid said - “Dexur has been a game-changer in utilizing data to prove the superiority of a home health or hospice agency's quality outcomes to its referring partners. Intrepid can identify specific physicians and Hospitals who refer us their patients relative to other agencies and then use Dexur’s marketing collateral and brochures to demonstrate the value of Intrepid’s services.”
As part of the the partnership with Dexur, Intrepid leverages key components of the platform including:
Parkview Health, a leading Indiana based Health system, has partnered with Gridlex’s Dexur provider app suite and advisory services to elevate its quality and value outcomes programs. As part of the partnership, Parkview not only utilizes Gridlex’s Dexur provider advisory services but also its unparalleled data and technology platform.
Diane Barnes, Director, Quality Resources, at Parkview said - “Dexur has been an integral partner in helping us elevate our quality and value programs. As most quality professionals know, monitoring quality programs is incredibly challenging with extremely complex calculations, risk adjustments, and significant lags in data. Dexur combines acute and non-acute Medicare claims data with technology to filter and collate the information effectively. Their enhanced algorithms simulate the impact of change of individual or multiple measures to program outcomes. Dexur’s statistical expertise and advisory services bring it all together to guide meaningful and effective strategy ”
About Gridlex & Dexur:
Gridlex’s Dexur healthcare data and technology platform utilizes CMS Medicare claims, which Gridlex Dexur directly acquires from CMS, to help hospitals and healthcare providers improve quality initiatives including: